(R)-N,1-Dimethylpyrrolidin-3-amine | 792970-21-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-N,1-Dimethylpyrrolidin-3-amine
• 英文别名: (3R)-N,1-dimethylpyrrolidin-3-amine
• CAS: 792970-21-9
• 化学式: C₆H₁₄N₂
• mdl: MFCD00059061
• 分子量: 114.19
• InChiKey: CZGIEJXGCLWRPY-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carboxylic acid 、 (R)-N,1-Dimethylpyrrolidin-3-amine 、 N,N-二异丙基乙胺 、 O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 在 水 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以to produce a purified product as pale yellow solid (80 mg) in 15.5% yield的产率得到2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-N-methyl-N-((R)-1-methylpyrrolidin-3-yl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carboxamide
  参考文献：
  名称：

  Fused ring compound for use as mineralocorticoid receptor antagonist

  摘要：

  本发明属于医学技术领域，特别涉及以下内容：一种由式（I）所代表的融合环化合物，用作矿物质皮质激素受体拮抗剂，其药学上可接受的盐和异构体；这些化合物的制备方法；含有这些化合物的制药制剂；以及这些化合物、其药学上可接受的盐或异构体在治疗和/或预防肾脏损伤、心血管疾病如高血压和/或内分泌疾病的药物制剂中的应用。其中X、Y1、Y2、Y3、R1、R2a、R2b、R3a、R3b、R4、Cy和n的定义如描述中所示。

  公开号：

  US08946279B2

文献信息

• [EN] 5H-ISOTHIAZOLO[4,5-C]PYRIDINE-3,4-DIONE OR 5H-PYRAZOLO[4,3-C]PYRIDIN-3,4-DIONE AS ANTIBACTERIAL COMPOUNDS<br/>[FR] 5H-ISOTHIAZOLO[4,5-C]PYRIDINE-3,4-DIONE OU 5H-PYRAZOLO[4,3-C]PYRIDINE-3,4-DIONE EN TANT QUE COMPOSÉS ANTIBACTÉRIENS
  申请人：REDX PHARMA PLC

  公开号：WO2015114317A1

  公开（公告）日：2015-08-06

  This invention relates to antibacterial drug compounds of formula (I) containing a fused isothiazolinone or pyrazolone ring and related compounds. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections and in methods of treating bacterial infections. Many of the antibacterial drug compounds contain a isothiazolinone or pyrazolone ring fused to a pyridone ring. The compounds have broad spectrum antibacterial activity but are particularly effective against Gram negative strains. wherein X is selected from S, SO, SO2, O and NR4;

  这项发明涉及公式（I）中含有融合异噻唑酮或吡唑酮环及相关化合物的抗菌药物化合物。它还涉及抗菌药物化合物的制药配方。它还涉及衍生物在治疗细菌感染和治疗细菌感染方法中的用途。许多抗菌药物化合物含有融合到吡啶酮环的异噻唑酮或吡唑酮环。这些化合物具有广谱抗菌活性，但对革兰氏阴性菌株特别有效。其中X从S、SO、SO2、O和NR4中选择。
• PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS
  申请人：Gilead Sciences, Inc.

  公开号：US20130164280A1

  公开（公告）日：2013-06-27

  The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.

  该发明提供了用于治疗病毒感染的化合物、药物可接受的盐和酯以及它们的组合物。这些化合物和组合物对于治疗包括人类呼吸道合胞病毒感染在内的肺病毒亚科病毒感染是有用的。
• Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist
  申请人：Huang Zhenhua

  公开号：US20130289029A1

  公开（公告）日：2013-10-31

  The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y 1 , Y 2 , Y 3 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , Cy and n are as presented in the description.

  本发明属于医学技术领域，具体涉及以下内容：一种由化学式（I）表示的融合环化合物，用作醛固酮受体拮抗剂，其药学上可接受的盐和异构体；这些化合物的制备方法；含有这些化合物的药物制剂；以及这些化合物、其药学上可接受的盐或其异构体在制备用于治疗和/或预防肾损伤、高血压等心血管疾病和/或内分泌疾病的药物时的应用。X、Y1、Y2、Y3、R1、R2a、R2b、R3a、R3b、R4、Cy和n的定义如描述中所示。
• [EN] HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME<br/>[FR] MODULATEURS DE HSP70 ET LEUR PROCÉDÉS DE FABRICATION ET LEUR UTILISATION
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2015175707A1

  公开（公告）日：2015-11-19

  The present invention provides compounds I and II and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.

  本发明提供化合物I和II及其组合物，用于调节Hsp70。在某些实施例中，本发明提供一种抑制Hsp70活性的方法。在某些实施例中，本发明提供一种治疗患有或易受Hsp70抑制性疾病、紊乱或病况的受试者的方法，包括向受试者施用所提供化合物的治疗有效量。在某些实施例中，本发明提供一种治疗或预防患有癌症的受试者的方法，包括向需要的患者施用所提供化合物的治疗有效量。
• [EN] 2-MORPHOLINO-4-PYRIMIDONE COMPOUND<br/>[FR] COMPOSE 2-MORPHOLINO-4-PYRIMIDONE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2006028290A1

  公开（公告）日：2006-03-16

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; 1 represents a C1-C12 alkyl; R2 represents a hydrogen atom, or the like; R' represents a C1-C6 alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C1-C6 alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式（I）所代表的化合物，其光学活性异构体，或其药用可接受盐：其中X代表CH或N；1代表C1-C12烷基；R2代表氢原子，或类似物；R'代表C1-C6烷基或类似物；q代表0或1至7的整数；Y代表C1-C6烷基或类似物；p代表0或1至5的整数；R代表2,3-二氢吲哚基或类似物，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，如神经退行性疾病（例如阿尔茨海默病）。